Epidemiology and Outcomes of Young-Onset Esophageal Adenocarcinoma: An Analysis from a Population-Based Database.
Journal
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
ISSN: 1538-7755
Titre abrégé: Cancer Epidemiol Biomarkers Prev
Pays: United States
ID NLM: 9200608
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
23
06
2020
revised:
20
08
2020
accepted:
05
10
2020
pubmed:
18
12
2020
medline:
27
11
2021
entrez:
17
12
2020
Statut:
ppublish
Résumé
Esophageal adenocarcinoma is a lethal cancer with rising incidence. There are limited data in younger (<50 years) patients with esophageal adenocarcinoma. We aimed to assess time trends in the incidence and outcomes of "young-onset" esophageal adenocarcinoma using a population-based database. We queried the Surveillance, Epidemiology, and End Results 9 database to identify patients with esophageal adenocarcinoma between 1975 and 2015. Patients were stratified into three age strata: <50, 50 to 69, and ≥70 years. Staging was stratified as localized, regional, and distant. Trends in incidence, disease stage, and survival were assessed in three periods (1975-89, 1990-99, and 2000-2015). Univariate and multivariate models were created to identify predictors of mortality. Esophageal adenocarcinoma incidence has increased in patients <50 years of age, with an annual percentage change of 2.9% (95% confidence interval, 1.4%-4.4%) from 1975 to 2015. Young-onset esophageal adenocarcinoma presented at more advanced stages (regional + distant) compared with older patients (84.9% vs. 67.3%; Young-onset esophageal adenocarcinoma, while uncommon, is rising in incidence. Concerningly, the proportion of advanced disease continues to increase. Young-onset esophageal adenocarcinoma also presents at more advanced stages, resulting in poorer esophageal adenocarcinoma-free survival. Patients with esophageal adenocarcinoma younger than 50 years present at more advanced stages with higher esophageal adenocarcinoma-specific mortality compared with older peers. Current diagnostic and management strategies for young-onset esophageal adenocarcinoma may need to be reevaluated.
Sections du résumé
BACKGROUND
Esophageal adenocarcinoma is a lethal cancer with rising incidence. There are limited data in younger (<50 years) patients with esophageal adenocarcinoma. We aimed to assess time trends in the incidence and outcomes of "young-onset" esophageal adenocarcinoma using a population-based database.
METHODS
We queried the Surveillance, Epidemiology, and End Results 9 database to identify patients with esophageal adenocarcinoma between 1975 and 2015. Patients were stratified into three age strata: <50, 50 to 69, and ≥70 years. Staging was stratified as localized, regional, and distant. Trends in incidence, disease stage, and survival were assessed in three periods (1975-89, 1990-99, and 2000-2015). Univariate and multivariate models were created to identify predictors of mortality.
RESULTS
Esophageal adenocarcinoma incidence has increased in patients <50 years of age, with an annual percentage change of 2.9% (95% confidence interval, 1.4%-4.4%) from 1975 to 2015. Young-onset esophageal adenocarcinoma presented at more advanced stages (regional + distant) compared with older patients (84.9% vs. 67.3%;
CONCLUSIONS
Young-onset esophageal adenocarcinoma, while uncommon, is rising in incidence. Concerningly, the proportion of advanced disease continues to increase. Young-onset esophageal adenocarcinoma also presents at more advanced stages, resulting in poorer esophageal adenocarcinoma-free survival.
IMPACT
Patients with esophageal adenocarcinoma younger than 50 years present at more advanced stages with higher esophageal adenocarcinoma-specific mortality compared with older peers. Current diagnostic and management strategies for young-onset esophageal adenocarcinoma may need to be reevaluated.
Identifiants
pubmed: 33328255
pii: 1055-9965.EPI-20-0944
doi: 10.1158/1055-9965.EPI-20-0944
pmc: PMC7855414
mid: NIHMS1637234
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
142-149Subventions
Organisme : NCI NIH HHS
ID : R01 CA241164
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002377
Pays : United States
Informations de copyright
©2020 American Association for Cancer Research.
Références
Cancer. 2013 Mar 15;119(6):1149-58
pubmed: 23303625
Cancer Manag Res. 2018 Apr 04;10:653-661
pubmed: 29670399
Am J Prev Med. 2017 Nov;53(5):567-575
pubmed: 28886964
J Data Sci. 2011 Oct 1;8(4):631-644
pubmed: 22375146
Horm Mol Biol Clin Investig. 2014 Jan;17(1):13-27
pubmed: 25372727
BMC Cancer. 2018 Mar 27;18(1):334
pubmed: 29587683
Pediatr Blood Cancer. 2008 Mar;50(3):588-93
pubmed: 17405155
Am J Gastroenterol. 2016 Jan;111(1):30-50; quiz 51
pubmed: 26526079
Am Surg. 2004 Nov;70(11):954-8
pubmed: 15586504
J Pediatr Surg. 2016 Nov;51(11):1812-1817
pubmed: 27558481
Medicine (Baltimore). 2014 Nov;93(23):e135
pubmed: 25415667
Ann Surg Oncol. 2013 Jun;20(6):1756-8
pubmed: 23508583
Dig Dis Sci. 2018 Nov;63(11):2880-2888
pubmed: 30109578
JAMA Surg. 2015 May;150(5):402-9
pubmed: 25806815
Dig Dis Sci. 2009 Aug;54(8):1708-12
pubmed: 19030991
PLoS One. 2019 Oct 21;14(10):e0224260
pubmed: 31634373
Int J Colorectal Dis. 2017 Aug;32(8):1147-1156
pubmed: 28389779
Gut. 2014 Jun;63(6):871-80
pubmed: 23853213
Dis Esophagus. 2017 Feb 1;30(3):1-8
pubmed: 27862652
Cancer Epidemiol Biomarkers Prev. 2006 May;15(5):872-8
pubmed: 16702363
J Neurogastroenterol Motil. 2018 Oct 01;24(4):559-569
pubmed: 30347935
Gastrointest Endosc. 2010 Jan;71(1):21-7
pubmed: 19748616
J Clin Oncol. 2014 Sep 20;32(27):2975-84
pubmed: 25002720
Gut. 2018 Feb;67(2):392-393
pubmed: 28389530
J Gastrointest Surg. 2013 Nov 15;:
pubmed: 24234242
JAMA. 2016 Jun 7;315(21):2284-91
pubmed: 27272580
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Gastroenterology. 2018 Dec;155(6):1716-1719.e4
pubmed: 30165046
Bol Asoc Med P R. 2006 Oct-Dec;98(4):270-5
pubmed: 19610568
Am J Surg. 2011 Nov;202(5):574-82
pubmed: 21872205
N Engl J Med. 2017 Jan 19;376(3):254-266
pubmed: 28099824
JAMA Surg. 2015 Jan;150(1):17-22
pubmed: 25372703
Oncogene. 2006 Jun 1;25(23):3346-56
pubmed: 16449976
World J Gastroenterol. 2019 Jun 28;25(24):3069-3078
pubmed: 31293342
Gastroenterology. 2018 Dec;155(6):1720-1728.e4
pubmed: 30165050
Cancer. 2010 Feb 1;116(3):758-65
pubmed: 19957323
Jpn J Clin Oncol. 2017 Nov 01;47(11):1010-1018
pubmed: 29048580
Oncoscience. 2016 Feb 01;3(1):42-8
pubmed: 26973859
World J Gastroenterol. 2014 Dec 14;20(46):17288-96
pubmed: 25516639
Am J Surg Pathol. 2016 Dec;40(12):e94-e102
pubmed: 27740970
NCHS Data Brief. 2017 Oct;(288):1-8
pubmed: 29155689
Gastrointest Endosc. 2008 Mar;67(3):394-8
pubmed: 18045592
N Engl J Med. 2014 Aug 28;371(9):836-45
pubmed: 25162890
Stat Methods Med Res. 2006 Dec;15(6):547-69
pubmed: 17260923
Clin Gastroenterol Hepatol. 2019 Aug;17(9):1756-1762
pubmed: 30267861
Annu Rev Cell Dev Biol. 2004;20:695-723
pubmed: 15473857